Akums Drugs & Pharmaceuticals announced robust financial results for the third quarter of FY26, showcasing a 14.8% YoY revenue growth to ₹1,160 crore. Adjusted EBITDA also saw a significant 21% YoY surge to ₹147 crore, driven by better capacity utilization. The company highlighted major achievements in global expansion, securing crucial EU GMP certifications for two facilities and receiving its first approval from the UK MHRA for a key tablet.
Akums Q3 FY26 Financial Highlights
Akums Drugs & Pharmaceuticals Ltd., a leading Contract Development and Manufacturing Organization (CDMO), declared its financial outcomes for the third quarter ending December 31, FY26. The company demonstrated strong momentum across its business segments, achieving a 14.8% year-over-year (YoY) revenue growth, with quarterly revenue reaching ₹1,160 crore, up from ₹1,010 crore in Q3 FY25.
Adjusted EBITDA improved substantially by 21.0% YoY, climbing to ₹147 crore in Q3 FY26, compared to ₹121 crore in the previous year’s corresponding quarter. This margin enhancement was attributed to improved capacity utilization and tighter overhead control. The Adjusted EBITDA Margin consequently rose to 12.7%.
Adjusted Profit After Tax (PAT) also grew by 29.5% YoY to ₹86 crore for the quarter.
Nine-Month Performance Summary
For the first nine months of FY26 (9MFY26), total revenue stood at ₹3,201 crore, marking a 4.5% increase over the ₹3,063 crore reported in 9MFY25. Adjusted EBITDA for the nine-month period grew by 1.0% YoY to ₹370 crore.
| Particulars (Rs in Crores) | Q3FY 26 | Q3FY 25 | YoY change | 9MFY26 | 9MFY25 | YoY change |
|---|---|---|---|---|---|---|
| Revenue | 1,160 | 1,010 | 14.8% | 3,201 | 3,063 | 4.5% |
| Adj EBITDA | 147 | 121 | 21.0% | 370 | 367 | 1.0% |
| Adj EBITDA Margin | 12.7% | 12.0% | — | 11.6% | 12.0% | — |
| Adj PAT | 86 | 66 | 29.5% | 193 | 190 | 1.6% |
Global Manufacturing Milestones Achieved
The company made significant strides in its global manufacturing ambitions. Akums successfully obtained the European Union Good Manufacturing Practice (EU GMP) certification for two of its facilities. This includes the renewal of the EU GMP approval for the Oral Solids’ plant and the new grant of certification for the Oral Liquids Plant.
Furthermore, Akums secured its inaugural approval from the UK MHRA for the manufacturing of Rivaroxaban tablets. Mr. Sandeep Jain, Managing Director, emphasized that these certifications validate the company’s robust quality systems and commitment to disciplined growth in regulated markets.
Mr. Sanjeev Jain, Managing Director, added that the focus on operational excellence aligns with the long-term global vision to expand responsibly across regulated territories and bolster worldwide partnerships.
Key Segment Performance Notes
The CDMO segment experienced revenue growth exceeding 16%, fueled by double-digit volume increases. Additionally, the international branded formulation segment more than doubled sequentially due to recovering demand in key markets.
Definition Clarification
For clarity, Adjusted EBITDA is calculated as profit/(loss) plus tax, finance costs, D&A, fair value changes to financial instruments, and exceptional items, minus other income. Adjusted PAT excludes the one-time impact of new Labour codes.
Source: BSE
